Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unveiling FOS as a Potential Diagnostic Biomarker and Emetine as a Prospective Therapeutic Agent for Diabetic Nephropathy

ABSTRACT: To gain a comprehensive understanding of emetine's impact on high glucose-induced M1 macrophage polarization in the pathogenesis of diabetic nephropathy (DN), we employed transcriptome sequencing. Our study included two experimental groups: the high glucose-induced damage group and the high glucose-induced damage with emetine pretreatment group. Differential gene expression analysis, accompanied by functional enrichment analysis, was conducted to identify crucial pathways and biological processes involved. This investigation provides significant insights into the role of emetine in DN, enhancing our knowledge regarding its underlying mechanisms. Furthermore, this research contributes to a deeper comprehension of the pathogenesis of diabetic nephropathy and offers valuable prospects for the development of potential therapeutic targets and strategies for diabetic nephropathy.

ORGANISM(S): Mus musculus

PROVIDER: GSE239385 | GEO | 2024/01/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Hyperactivation of YAP/TAZ drives alterations in mesangial cells through stabilization of N-MYC in diabetic nephropathy

Project description:Mesangial cells (MCs) in the kidney are central to maintaining glomerular integrity, and their impairment leads to major glomerular diseases including diabetic nephropathy (DN). Although high blood glucose elicits abnormal alterations in MCs, the underlying molecular mechanism is poorly understood. Here, we show that YAP and TAZ, the final effectors of the Hippo pathway, are highly increased in MCs of patients with DN and of Zucker diabetic fatty rats. Moreover, high glucose directly induces activation of YAP/TAZ through the canonical Hippo pathway in cultured MCs. Hyperactivation of YAP/TAZ in mouse model MCs recapitulates the hallmarks of DN, including excessive proliferation of MCs and extracellular matrix deposition, endothelial cell impairment, glomerular sclerosis, albuminuria, and reduced glomerular filtration rate. Mechanistically, activated YAP/TAZ bind and stabilize N-Myc protein, one of the Myc family of oncogenes. N-Myc stabilization leads to aberrant enhancement of its transcriptional activity and eventually to MC impairments and DN pathogenesis. Together, these findings shed light on how high blood glucose in diabetes mellitus leads to DN and support a rationale that lowering blood glucose in diabetes mellitus could delay DN pathogenesis.

2022-02-01 | GSE195751 | GEO

Long non-coding RNA Dlx6os1 serves as a potential treatment target for diabetic nephropathy via regulating multiple apoptosis and inflammation-related pathways derived from RNA-Seq

Project description:We investigated the effect of long non-coding RNA (lncRNA) Dlx6os1 silencing on cell proliferation, apoptosis, fibrosis, and further explored its influence on mRNA expression profile in mouse mesangial cells (MMCs) of diabetic nephropathy (DN) cellular model. DN cellular model was constructed in SV40 MES13 cells (MMCs) under high glucose condition (under 30 mmol/L glucose culture).

2020-08-11 | GSE145301 | GEO

Identification of Hub Genes and Potential ceRNA Networks of Diabetic Cardiomyopathy [miRNA-seq]

Project description:To explore the unique pathogenesis of DCM and analyzed the differences in gene expression, associated pathways and immune cell infiltration among different organs that are targeted by high glucose by bioinformatics-based strategy. In order to find the specific factors that trigger DCM, we contrasted the gene profile of DCM to that of other diabetic diseases including diabetic peripheral neuropathy (DPN) and nephropathy (DN). we performed RNA-seq and miRNA sequencing on heart tissue from db/db mice to explore the transcriptome alterations in DCM pathogenesis including lncRNA, miRNA and mRNA.

2023-05-10 | GSE211107 | GEO

Identification of Hub Genes and Potential ceRNA Networks of Diabetic Cardiomyopathy [RNA-seq]

2023-05-10 | GSE211106 | GEO

Project description:Diabetic mellitus (DM) is a disease that affects glucose homeostasis and has cause of complications, such as diabetic nephropathy (DN). For diagnose of the early DN, microalbuminuria is one of the mostly used biomarker currently. However, more early diagnostic biomarkers are desired rather than microalbuminuria.

2018-05-31 | PXD008683 | JPOST Repository

Altered expression of long non-coding and messenger RNAs in diabetic nephropathy following treatment with rosiglitazone

Project description:Diabetic nephropathy (DN) is characterized by metabolic disorder and inflammation. However, the regulatory effects that long noncoding RNAs (lncRNAs) have on the pathogenesis of DN and on the efficacy of rosiglitazone treatment has yet to be clearly defined. Herein, we performed unbiased RNA sequencing to characterize the transcriptomic profiles in db/db diabetic mouse model with or without rosiglitazone treatment that served to improve the phenotypes of DN. Differential expression analysis revealed that those genes that had their expression restored following treatment with rosiglitazone are likely involved in protection against DN. Our data elucidate the novel renoprotective molecular mechanism of PPARγ agonists and propose lncRNA targets for diabetic nephropathy treatment.

2020-01-14 | GSE139987 | GEO

Investigating HMGB1 as a Potential Serum Biomarker for Early Diabetic Nephropathy Monitoring by Quantitative Proteomics

Project description:Current diagnostic methods for diabetic nephropathy (DN) lack precision, especially in early stages and monitoring progression. This study aims to find potential biomarkers for DN progression and evaluate their accuracy. Using serum samples from healthy controls (NC), diabetic patients (DM), early-medium stage DN (DN-EM), and late-stage DN (DN-L), researchers employed quantitative proteomics and Mfuzz clustering analysis revealed 15 proteins showing increased expression during DN progression, hinting at their biomarker potential. Combining Mfuzz clustering with weighted gene co-expression network analysis (WGCNA) highlighted five candidates (HMGB1, CD44, FBLN1, PTPRG, and ADAMTSL4). HMGB1 emerged as a promising biomarker, closely correlated with renal function changes. Experimental validation supported HMGB1’s upregulation under high glucose conditions, reinforcing its potential as an early detection biomarker for DN. This research advances DN understanding and identifies five potential biomarkers, notably HMGB1, as a promising early monitoring target. These findings set the stage for future clinical diagnostic applications in DN.

2023-12-28 | PXD047872 | Pride

Expression data from kidney in type 2 diabetic db/db mice

Project description:Diabetic nephropathy(DN) is a common diabetic microvascular complication, the underlying mechanisms involved in DN remain to be elucidated. We used microarrays to explore the global profile of gene expression for better understanding the molecular mechanism of diabetic nephropathy in type 2 diabetic db/db mice.

2017-06-10 | GSE87359 | GEO

Deficiency of C3a receptor attenuates the development of diabetic nephropathy (Control Group)

Project description:Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and end-stage renal disease. Emerging evidence suggests that complement activation is involved in the pathogenesis of DN. The aim of this study was to investigate the pathogenic role of C3a and C3a receptor (C3aR) in DN. The expression of C3aR was examined in the renal specimen of DN patients. Using a C3aR gene knockout mice (C3aR-/-), we evaluated kidney injury in diabetic mice. The mouse gene expression microarray was performed to further explore the pathogenic role of C3aR. Then the underlying mechanism was investigated in vitro with macrophage treated with C3a. Compared with normal controls, the renal expression of C3aR was significantly increased in DN patients. C3aR-/- diabetic mice developed less severe diabetic renal damage compared with WT diabetic mice, exhibiting significantly lower level of albuminuria and milder renal pathological injury. Microarray profiling uncovered significantly suppressed inflammatory responses and T cell adaptive immunity in C3aR-/- diabetic mice compared with WT diabetic mice and this result was further verified by immunohistochemical staining of renal CD4+, CD8+ T cells and macrophages infiltration. In vitro study demonstrated C3a can enhance macrophages secreted cytokines which could induce inflammatory responses and differentiation of T cell lineage. In conclusion, C3aR deficiency could attenuate diabetic renal damage through suppressing inflammatory responses and T cell adaptive immunity, possibly by influencing macrophages secreted cytokines. Thus, C3aR may be a promising therapeutic target for DN.

2020-04-10 | GSE133596 | GEO

Deficiency of C3a receptor attenuates the development of diabetic nephropathy (Diabetic Group)

2020-04-10 | GSE133597 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data